血液系统恶性肿瘤中21号染色体获得:从唐氏综合征儿童白血病研究中获得的启示
综述整合21号染色体获得在血液系统恶性肿瘤中的作用,以唐氏综合征相关白血病为范式,梳理21三体、剂量敏感基因及协同遗传事件与白血病发生的关系,并指出该领域研究前景。
要点
- 21号染色体获得在多种急性白血病中常见,可见于高达35%的病例。
- 唐氏综合征儿童伴组成性21三体,急性白血病风险较其他儿童升高。
- 21三体为发育阶段和细胞背景提供易感基础,并与白血病进展中的额外遗传事件协同。
核心结论
- 21三体在启动易感发育阶段和细胞背景中起关键作用,并与白血病进展中的额外遗传事件协同。
- 综述以唐氏综合征白血病为范式,整合21三体、关键剂量敏感21号染色体基因及相关机制的认识。
研究设计与样本
- 综述,以唐氏综合征相关白血病为范式,整合21号染色体获得在血液系统恶性肿瘤中作用的研究。
主要发现
- 21号染色体获得在多种急性白血病中常见,可见于高达35%的病例。
- 唐氏综合征儿童伴组成性21三体,急性白血病风险较其他儿童升高。
- 唐氏综合征相关白血病的临床结局多年来通过国际合作组推动的统一治疗方案得到改善。
- 近期研究刻画了唐氏综合征相关白血病的遗传图谱,揭示21三体与白血病进展中额外遗传事件的协同作用。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Structural and numerical alterations of chromosome 21 are extremely common in hematological malignancies. While the functional impact of chimeric transcripts from fused chromosome 21 genes such as TEL-AML1, AML1-ETO, or FUS-ERG have been extensively studied, the role of gain of chromosome 21 remains largely unknown. Gain of chromosome 21 is a frequently occurring aberration in several types of acute leukemia and can be found in up to 35% of cases. Children with Down syndrome (DS), who harbor constitutive trisomy 21, highlight the link between gain of chromosome 21 and leukemogenesis, with an increased risk of developing acute leukemia compared with other children. Clinical outcomes for DS-associated leukemia have improved over the years through the development of uniform treatment protocols facilitated by international cooperative groups. The genetic landscape has also recently been characterized, providing an insight into the molecular pathogenesis underlying DS-associated leukemia. These studies emphasize the key role of trisomy 21 in priming a developmental stage and cellular context susceptible to transformation, and have unveiled its cooperative function with additional genetic events that occur during leukemia progression. Here, using DS-leukemia as a paradigm, we aim to integrate our current understanding of the role of trisomy 21, of critical dosage-sensitive chromosome 21 genes, and of associated mechanisms underlying the development of hematological malignancies. This review will pave the way for future investigations on the broad impact of gain of chromosome 21 in hematological cancer, with a view to discovering new vulnerabilities and develop novel targeted therapies to improve long term outcomes for DS and non-DS patients.
引用
- Laurent AP, Kotecha RS, Malinge S, et al. Gain of chromosome 21 in hematological malignancies: lessons from studying leukemia in children with Down syndrome. Leukemia. 2020. PMID: 32433508. doi:10.1038/s41375-020-0854-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。